CTLA4 and neoplasm: In colorectal cancer models, the combination of CTLA-4 inhibition with Treg depletion via Ipilimumab has improved therapeutic efficacy by reducing Treg presence within the tumor and promoting the activation of effector T cells (49).To optimize these strategies, innovative approaches such as antibody-drug conjugates have been developed.